Alembic Pharmaceuticals Limited (APLLTD) - Total Assets
Based on the latest financial reports, Alembic Pharmaceuticals Limited (APLLTD) holds total assets worth Rs83.97 Billion INR (≈ $908.10 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Alembic Pharmaceuticals Limited to assess how comfortably operating cash covers total debt obligations.
Alembic Pharmaceuticals Limited - Total Assets Trend (2011–2025)
This chart illustrates how Alembic Pharmaceuticals Limited's total assets have evolved over time, based on quarterly financial data. See Alembic Pharmaceuticals Limited (APLLTD) shareholders funds for net asset value and shareholders' equity analysis.
Alembic Pharmaceuticals Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Alembic Pharmaceuticals Limited's total assets of Rs83.97 Billion consist of 52.6% current assets and 47.4% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 1.2% |
| Accounts Receivable | Rs14.00 Billion | 18.0% |
| Inventory | Rs22.88 Billion | 29.4% |
| Property, Plant & Equipment | Rs33.61 Billion | 43.2% |
| Intangible Assets | Rs0.00 | 0.0% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Alembic Pharmaceuticals Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see APLLTD company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alembic Pharmaceuticals Limited's current assets represent 52.6% of total assets in 2025, a decrease from 64.2% in 2011.
- Cash Position: Cash and equivalents constituted 1.2% of total assets in 2025, up from 0.8% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is property, plant & equipment at 43.2% of total assets.
Alembic Pharmaceuticals Limited Competitors by Total Assets
Key competitors of Alembic Pharmaceuticals Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
|
China | CN¥2.30 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥8.59 Billion |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
China | CN¥925.41 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩605.27 Billion |
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Samjin Pharm
KO:005500
|
Korea | ₩449.14 Billion |
Alembic Pharmaceuticals Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.59 | 1.73 | 2.52 |
| Quick Ratio | 0.66 | 0.81 | 1.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs16.19 Billion | Rs15.91 Billion | Rs15.39 Billion |
Alembic Pharmaceuticals Limited - Advanced Valuation Insights
This section examines the relationship between Alembic Pharmaceuticals Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.94 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 20.6% |
| Total Assets | Rs77.73 Billion |
| Market Capitalization | $1.71 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Alembic Pharmaceuticals Limited's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Alembic Pharmaceuticals Limited's assets grew by 20.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Alembic Pharmaceuticals Limited (2011–2025)
The table below shows the annual total assets of Alembic Pharmaceuticals Limited from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs77.73 Billion ≈ $840.61 Million |
+20.59% |
| 2024-03-31 | Rs64.46 Billion ≈ $697.07 Million |
+4.25% |
| 2023-03-31 | Rs61.83 Billion ≈ $668.65 Million |
-13.19% |
| 2022-03-31 | Rs71.22 Billion ≈ $770.22 Million |
+6.16% |
| 2021-03-31 | Rs67.09 Billion ≈ $725.55 Million |
+12.02% |
| 2020-03-31 | Rs59.89 Billion ≈ $647.69 Million |
+25.35% |
| 2019-03-31 | Rs47.78 Billion ≈ $516.70 Million |
+21.23% |
| 2018-03-31 | Rs39.41 Billion ≈ $426.21 Million |
+46.69% |
| 2017-03-31 | Rs26.87 Billion ≈ $290.55 Million |
+9.24% |
| 2016-03-31 | Rs24.59 Billion ≈ $265.97 Million |
+49.86% |
| 2015-03-31 | Rs16.41 Billion ≈ $177.49 Million |
+34.76% |
| 2014-03-31 | Rs12.18 Billion ≈ $131.70 Million |
+16.22% |
| 2013-03-31 | Rs10.48 Billion ≈ $113.32 Million |
-0.39% |
| 2012-03-31 | Rs10.52 Billion ≈ $113.76 Million |
+24.69% |
| 2011-03-31 | Rs8.44 Billion ≈ $91.24 Million |
-- |
About Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal healt… Read more